These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11033496)

  • 1. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
    Detry-Morel M; Dutrieux C
    J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
    Greenfield DS; Liebmann JM; Ritch R
    J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
    thoe Schwartzenberg GW; Buys YM
    Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
    Melamed S; David R
    Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group.
    Lee DA; Gornbein J; Abrams C
    J Ocul Pharmacol Ther; 2000 Feb; 16(1):3-18. PubMed ID: 10673126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
    Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
    J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
    Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension].
    Shi JM; Jiang YQ
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):263-6. PubMed ID: 12575311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
    Katz G; Dubiner H; Samples J; Vold S; Sall K
    JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The ocular hypotensive effect and safety of 0.2% brimonidine].
    Yu M; Li Y; Ge J
    Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
    Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
    Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment].
    Titouamane S; Baudouin C
    J Fr Ophtalmol; 2002 Jun; 25(6):568-75. PubMed ID: 12223942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes.
    Thomas R; Parikh R; Muliyil J; George R; Paul P; Abraham LM
    Indian J Ophthalmol; 2003 Jun; 51(2):123-8. PubMed ID: 12831141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Side-effect profile of brimonidine tartrate in children.
    Al-Shahwan S; Al-Torbak AA; Turkmani S; Al-Omran M; Al-Jadaan I; Edward DP
    Ophthalmology; 2005 Dec; 112(12):2143. PubMed ID: 16225927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
    Katz LJ
    J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
    Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
    Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
    Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy.
    Motolko MA
    Curr Med Res Opin; 2008 Sep; 24(9):2663-7. PubMed ID: 18691444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is brimonidine ophthalmic a safe therapy for infants?
    Daubert GP
    J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.